(Q34974828)

5 August 2017

1 reference

title

Use of the dopamine agonist cabergoline in the treatment of movement disorders (English)

1 reference

5 August 2017

0 references

K Ray Chaudhuri

1 reference

5 August 2017

Aimee Di Marco

1 reference

5 August 2017

Linda S Appiah-Kubi

series ordinal

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

Expert Opinion on Pharmacotherapy

5 August 2017

published in

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

1481-1487

1 reference

Are dopamine receptor agonists neuroprotective in Parkinson's disease?

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

Improvement of sleep architecture in PD with subthalamic nucleus stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

Etiology and pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

The use of dopamine agonists in very elderly patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

Absence of orgasm-induced prolactin secretion in a healthy multi-orgasmic male subject

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

Waking up to sleep episodes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

Hypocretin (orexin) deficiency in human narcolepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.10.1481

10.1517/14656566.3.10.1481

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference